Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
08/04/2024 12:59
April 8 (Reuters) - Intelgenx Technologies Corp
IGX.TO :
* INTELGENX ANNOUNCES FIRST PARKINSON’S DISEASE PATIENTS
DOSED
WITH MONTELUKAST VERSAFILM® IN PHASE 2 ‘MONTPARK’ CLINICAL TRIAL
Source text for Eikon: ID:nGNX5Lzqj
Further company coverage: IGX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA